CN103301413A - Traditional Chinese medicine composition for treating hyperlipemia and hyperglycemia - Google Patents
Traditional Chinese medicine composition for treating hyperlipemia and hyperglycemia Download PDFInfo
- Publication number
- CN103301413A CN103301413A CN2013102817934A CN201310281793A CN103301413A CN 103301413 A CN103301413 A CN 103301413A CN 2013102817934 A CN2013102817934 A CN 2013102817934A CN 201310281793 A CN201310281793 A CN 201310281793A CN 103301413 A CN103301413 A CN 103301413A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- radix
- hyperglycemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 113
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 201000001421 hyperglycemia Diseases 0.000 title claims abstract description 36
- 201000005577 familial hyperlipidemia Diseases 0.000 title abstract description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 32
- 210000000582 semen Anatomy 0.000 claims abstract description 18
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 9
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 9
- 235000004879 dioscorea Nutrition 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 7
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000008280 blood Substances 0.000 claims description 47
- 210000004369 blood Anatomy 0.000 claims description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 18
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 16
- 239000012567 medical material Substances 0.000 claims description 16
- 238000012360 testing method Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 235000005903 Dioscorea Nutrition 0.000 claims description 8
- 235000000504 Dioscorea villosa Nutrition 0.000 claims description 8
- 230000006837 decompression Effects 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000012467 final product Substances 0.000 claims description 6
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 2
- 244000281702 Dioscorea villosa Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 42
- 240000002853 Nelumbo nucifera Species 0.000 abstract description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract description 3
- 241000427159 Achyranthes Species 0.000 abstract 1
- 240000005528 Arctium lappa Species 0.000 abstract 1
- 235000003130 Arctium lappa Nutrition 0.000 abstract 1
- 235000008078 Arctium minus Nutrition 0.000 abstract 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 240000005717 Dioscorea alata Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 241001071917 Lithospermum Species 0.000 abstract 1
- 241000488974 Loranthus Species 0.000 abstract 1
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 235000001188 Peltandra virginica Nutrition 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 244000153955 Reynoutria sachalinensis Species 0.000 abstract 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 230000003071 parasitic effect Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 16
- 239000008103 glucose Substances 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 238000003304 gavage Methods 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 230000001603 reducing effect Effects 0.000 description 14
- 230000001717 pathogenic effect Effects 0.000 description 13
- 239000013641 positive control Substances 0.000 description 13
- 210000003734 kidney Anatomy 0.000 description 11
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 10
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 8
- 241000234273 Dioscorea Species 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000000232 gallbladder Anatomy 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000000916 dilatatory effect Effects 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000005906 menstruation Effects 0.000 description 4
- 230000000291 postprandial effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000345998 Calamus manan Species 0.000 description 3
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010013954 Dysphoria Diseases 0.000 description 3
- 239000010282 Emodin Substances 0.000 description 3
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 3
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 3
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 description 3
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 3
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 3
- 208000031971 Yin Deficiency Diseases 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 3
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 description 3
- 229940100243 oleanolic acid Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 3
- 230000003405 preventing effect Effects 0.000 description 3
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 235000012950 rattan cane Nutrition 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 235000019615 sensations Nutrition 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- WUYQEGNOQLRQAQ-CQSZACIVSA-N (+)-pronuciferine Chemical compound C([C@H]1N(C)CCC=2C=C(C(=C3C=21)OC)OC)C13C=CC(=O)C=C1 WUYQEGNOQLRQAQ-CQSZACIVSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000012895 Gastric disease Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241000124463 Paeonia sterniana Species 0.000 description 2
- 240000007711 Peperomia pellucida Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 206010048214 Xanthoma Diseases 0.000 description 2
- 206010048215 Xanthomatosis Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- -1 anthracene ester Chemical class 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 208000017561 flaccidity Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000018556 stomach disease Diseases 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- WUYQEGNOQLRQAQ-UHFFFAOYSA-N (+)-pronuciferine Natural products C1=2C3=C(OC)C(OC)=CC=2CCN(C)C1CC13C=CC(=O)C=C1 WUYQEGNOQLRQAQ-UHFFFAOYSA-N 0.000 description 1
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- BZFBDUQOBQHBSZ-DLCQERRASA-N (3s,8r,9s,10r,13s,14s,17s)-17-[3-(dimethylamino)propyl-methylamino]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol;dihydrochloride Chemical compound Cl.Cl.C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](N(C)CCCN(C)C)[C@@]1(C)CC2 BZFBDUQOBQHBSZ-DLCQERRASA-N 0.000 description 1
- HSTZMXCBWJGKHG-UHFFFAOYSA-N (E)-piceid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000219317 Amaranthaceae Species 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001098038 Callerya cinerea Species 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 241000334119 Coturnix japonica Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000131458 Elsholtzia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 241000561703 Kadsura heteroclita Species 0.000 description 1
- 241001083838 Lardizabalaceae Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000122904 Mucuna Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028665 Myxoedema Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241000209477 Nymphaeaceae Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- JCTYWRARKVGOBK-CQSZACIVSA-N Remerin Chemical compound C12=C3C4=CC=CC=C4C[C@H]1N(C)CCC2=CC1=C3OCO1 JCTYWRARKVGOBK-CQSZACIVSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- JCTYWRARKVGOBK-UHFFFAOYSA-N Roemerine Natural products C12=C3C4=CC=CC=C4CC1N(C)CCC2=CC1=C3OCO1 JCTYWRARKVGOBK-UHFFFAOYSA-N 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000800405 Spatholobus suberectus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Natural products C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 229930185278 anthraglycoside Natural products 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000001466 anti-adreneric effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 208000003786 myxedema Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 1
- OISYIJRGMYJBRH-UHFFFAOYSA-N physcione Natural products COc1cc(O)c2C(=O)c3ccc(O)cc3C(=O)c2c1 OISYIJRGMYJBRH-UHFFFAOYSA-N 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229960003764 polydatin Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229930001545 pronuciferine Natural products 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- KKOXKGNSUHTUBV-UHFFFAOYSA-N racemic zingiberene Natural products CC(C)=CCCC(C)C1CC=C(C)C=C1 KKOXKGNSUHTUBV-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000009874 shenqi Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- HSTZMXCBWJGKHG-CUYWLFDKSA-N trans-piceid Polymers O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-CUYWLFDKSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- KKOXKGNSUHTUBV-LSDHHAIUSA-N zingiberene Chemical compound CC(C)=CCC[C@H](C)[C@H]1CC=C(C)C=C1 KKOXKGNSUHTUBV-LSDHHAIUSA-N 0.000 description 1
- 229930001895 zingiberene Natural products 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating hyperlipemia and hyperglycemia, and relates to the field of a traditional Chinese medicine. The traditional Chinese medicine composition is prepared from the following raw materials: 10-20 parts of burdock, 12-18 parts of common yam rhizome, 6-10 parts of semen cassia, 10-15 parts of rhizoma alismatis, 10-20 radix curcumae longae, 12-16 parts of tuckahoe, 6-9 parts of lithospermum, 20-30 parts of caulis spatholobi, 20-30 parts of hawthorn, 10-16 parts of radix bupleuri, 12-18 parts of parasitic loranthus, 15-25 parts of lotus leaf, 10-20 parts of giant knot weed, 6-12 parts of radix paeoniae alba, 15-20 parts of achyranthes root, and 10-15 parts of liquorice. The traditional Chinese medicine composition disclosed by the invention has a good treatment effect in the aspect of treatment of hyperglycemia and/or hyperlipidemia, especially on a sufferer with hyperlipidemia and hyperglycemia, and has significant clinical popularization value.
Description
Technical field
The present invention relates to the Chinese medicine technical field, be specifically related to a kind of Chinese medicine composition that hyperlipidemia merges hyperglycemia for the treatment of.
Background technology
Diabetes are a kind of regular incidences of harm humans health, and global diabetics number increases rapidly with surprising rapidity, Epidemiological study demonstration in 2003, and there are nearly 200,000,000 diabeticss in the whole world, estimates that this numeral in 2025 will be above 300,000,000.Along with the fast development of China's economy, diabetics also presents the situation of growth at full speed.Over nearly 20 years, China's diabetes prevalence is increased to 3.21% from less than 1%.With present growth trend, expect 2025, the diabetics of China will be above 5,000 ten thousand.At present, China has become the second in the world diabetes big country that is only second to India.Diabetic complication harm is serious, and in China, diabetics has the chronic complicating diseases, and the person is quite general; Wherein be associated with hyperglycemia, cardiovascular and cerebrovascular disease, eye and nephropathy change person and all account for about 1/3, the person accounts for more than half the neuropathy.Angiopathy such as the prevalence of hypertension, hyperlipidemia, cerebrovascular and cardiovascular pathological changes, significantly increases before.Though the prevalence of cardiovascular complication is low than western countries, become China's diabetes disability rate and fatality rate is the highest, harm is maximum chronic complicating diseases.
As everyone knows, the Other Risk Factors such as hypertension, dyslipidemia, advanced age, obesity, smoking, hyperglycemia can be worked in coordination with generation, the development of aggravation hyperlipidemia.Wherein hyperglycemia and hyperlipidemia are " twin sisters ", and are the diseases of a reciprocal causation.Hyperlipemia can be divided into constitutional and Secondary cases two classes usually.Constitutional is with congenital and hereditary relevant, and that comparatively common is the latter clinically.Secondary cases is multiple is born in metabolic disorders (diabetes, hypertension, myxedema, hypothyroidism, obesity, hepatorenal disease, adrenal cortex function are hyperfunction), or with other factor ages, sex, season, drink, smoking, diet, physical exertion, psychentonia, emotional activity etc. is relevant.Mainly to be lipid deposit caused xanthoma and lipid deposits caused arteriosclerosis at blood vessel endothelium in intradermal in the clinical manifestation of hyperlipemia.Although hyperlipemia can cause xanthoma, its incidence rate is also not bery high; And atherosclerotic generation and development are a kind of slowly progressive processes.Therefore under normal conditions, most of patients and non-evident sympton and unusual sign.Many people are because other reasons carries out just having found when blood biochemical is checked that blood plasma lipoprotein level raises.
Hyperglycemia and hyperlipidemia such as shade with, but in existing clinical treatment, lack the simultaneously effective medicine of two kinds of diseases, blindly with clinical blood sugar lowering chemicals commonly used and the coupling of blood fat reducing chemicals not only drug effect can not guarantee, can cause larger cardiovascular risk on the contrary.In addition, the toxic and side effects of existing clinical chemistry medicine is large, and medical expense is high, has caused great psychological burden and economic pressures for hyperlipidemia and/or hyperpietic.Therefore develop the low treatment hyperglycemia of a kind of determined curative effect, untoward reaction and/or the medicine of hyperlipidemia and then can greatly reduce patient's misery, improve patient's life quality and quality of life.
Chinese medicine hyperlipidemia or hyperglycemia historical of long standing and well established, and as an importance of modern cardiovascular disease Comprehensive Treatment, more and more receive publicity in recent years.People seek single pharmaceutically active ingredient from Chinese traditional herbs or compound recipe is treated cancer tool challenge.Make a general survey of the research direction of world's new drug, mainly be single chemicals and preparations thereof of research and development the eighties in the past, begins to develop biotechnology and natural medicinal plants after the eighties, and the drug research direction is tending towards multiformity.In conjunction with the modern Chinese medicine theory of development, from improving the angle of curative effect of medication, reduction side effect, through Chinese medicine ingredients being screened the preparation that extraction and/or compatibility make, its side effect is little, and is safe, has the advantage that chemical synthetic drug can not be compared.
Summary of the invention
Deficiency for the high existing treatment of present hyperglycemia and/or hyperlipidemia medicine somewhat expensive, side effect, first purpose of the present invention is to provide a kind of Chinese medicine composition of alcoholic liver, this Chinese medicine composition has determined curative effect, the low technical advantage of side effect aspect treatment hyperglycemia and/or the hyperlipidemia, and cheap, be fit to clinical use.
The present invention treats the Chinese medicine composition that hyperlipidemia merges hyperglycemia, is made by the raw material of following weight portion: Fructus Arctii 10-20 part, Rhizoma dioscoreae 12-18 part, Semen Cassiae 6-10 part, Rhizoma Alismatis 10-15 part, Rhizoma Curcumae Longae 10-20 part, Poria 12-16 part, Radix Arnebiae (Radix Lithospermi) 6-9 part, Caulis Spatholobi 20-30 part, Fructus Crataegi 20-30 part, Radix Bupleuri 10-16 part, Herba Taxilli 12-18 part, Folium Nelumbinis 15-25 part, Rhizoma Polygoni Cuspidati 10-20 part, Radix Paeoniae Alba 6-12 part, Radix Achyranthis Bidentatae 15-20 part and Radix Glycyrrhizae 10-15 part.
The Fructus Arctii nature and flavor are hot, bitter, cold, and dispelling wind and heat pathogens, detoxifcation rash, the loose swollen effect of sore-throat relieving are arranged, and have the expert to find that also it has certain defecating feces excretion.Its root leaf is smash deposited with salt or is endured cream and is coated with the subsides affected part, can control all toxic swellings.The modern study discovery, Fructus Arctii has hypoglycemic activity, and experiment finds that it can resist nephropathy to become, and suppresses the effect of the drainage of urine protein, and diabetic nephropathy is had certain therapeutical effect; In addition its can be antibiotic, antiviral, raising immunity, diabetes ward mate is hypoimmunity often, easy diseases caused by exogenous pathogenic factor, Fructus Arctii is highly profitable to this.
Rhizoma Dioscoreae is as health food, and the history China has more than 2000 year at least become book in the Shennong's Herbal of the Eastern Han Dynasty Rhizoma Dioscoreae to be classified as top grade, but Rhizoma Dioscoreae at that time may be wild, does not also enter the artificial culture stage.To the Tang Dynasty, " 4 o'clock bun will " quote " mountain occupies and wants art " that Taoist priest king shows, and comparatively detailed record has been done in the DUISHANYAO cultivation.The traditional Chinese medical science is thought, Rhizoma Dioscoreae " main damaging the spleen and stomach tonify deficiency, except cold and heat pathogen, invigorating the spleen and replenishing QI power, longue meat takes normal hearing and eyesight for a long time ".Many classic doctor's nationalitys all DUISHANYAO have been done very high evaluation.Among the people, Rhizoma Dioscoreae is on record excellent tonic product.It contains the compositions such as protein, saccharide, vitamin, fat, choline, amylase, also contains the indispensable inorganic salt of human body and the trace element such as iodine, calcium, ferrum, phosphorus.The Rhizoma dioscoreae sweet in the mouth, property is flat.Return spleen, lung, kidney channel.Has the spleen reinforcing nourishing the stomach, the lung benefiting that promotes the production of body fluid, the effect of the kidney invigorating arresting seminal emission.Clinically cure mainly that insufficiency of the spleen lack of appetite, incessant chronic diarrhea, the deficiency of the lung are breathed with cough, emission due to deficiency of the kidney, leukorrhagia, frequent micturition, deficiency-heat quench one's thirst.
Semen Cassiae is the mature seed of leguminous plant Semen Cassiae, also is called Semen Cassiae.Shennong's Herbal record Semen Cassiae sweetness and bitterness is slightly cold, and returns liver, gallbladder, kidney three warps, has liver heat removing and eyesight improving, loosening bowel to relieve constipation, and the function of lipid-lowering weight-reducing can be used for having a headache dizzy, and conjunctival congestion is dim-sighted, and constipations etc. are used for again the treatment of hyperglycemia in recent years clinically.Semen Cassiae contains the anthraglycosides material, produces emodin, physcione, chrysophanic acid, chrysophanol and glucose etc. after decomposing.Experiment showed, that Semen Cassiae has blood pressure lowering, blood fat reducing, the effect such as antibiotic, being used for the treatment of hyperlipemia has certain curative effect.Except medicinal ingredient, Semen Cassiae also contains multivitamin and the aminoacid that enriches, carbohydrate etc.
Rhizoma Alismatis (rhizome) is again one of traditional Chinese medicine.Theory of Chinese medical science thinks that it is cold in nature, has the effect of promoting diuresis to eliminate damp pathogen; Cure mainly expel the heat-evil treating stranguria, dysuria, the puckery pain of pyretic stranguria, edema distension, have loose bowels, the disease such as dizziness due to fluid-retention.Modern medicine study, Rhizoma Alismatis can reduce serum total cholesterol and triacylglycerol content, slow down atherogenesis; Rhizoma Alismatis and preparation modern times thereof also are used for the treatment of auditory vertigo, dyslipidemia, seminal emission, fatty liver and diabetes etc.
Rhizoma Curcumae Longae: medicinal its rhizome, bitter in the mouth is hot, and is warm in nature, returns liver, spleen two warps.Main component contains volatile oil, such as Rhizoma Curcumae Longae essence, dehydrogenation Rhizoma Curcumae Longae essence, zingiberene etc.Rhizoma Curcumae Longae can be declared the gas in the logical blood, the capable and blood of gas is not stopped up stagnant, and the effect of inducing menstruation to relieve menalgia is arranged.Rhizoma Curcumae Longae can increase bile formation and secretion, and cholic acid and the cholesterol drained in the feces are increased.Although Rhizoma Curcumae Longae promotes a little less than the effect of bile secretion, and is more lasting.Rhizoma Curcumae Longae can also increase fibrinous lytic activity, and antithrombotic effect is arranged.Attention: find according to pharmacological research, Rhizoma Curcumae Longae has the effect in excited uterus, can make uterine contraction, the careful usefulness of pregnant woman.
Poria is commonly called as Poria, Song Ling, Poria, and for colonizing in the fungi plant on the pinaster root, shape is as Rhizoma Dioscoreae esculentae, crust pitchy, the inside white or pink.Ancients claim that Poria is " refreshing medicine " at 4 o'clock, because its effect is very extensive, regardless of the four seasons, with it and various compatibility of drugs, no matter cold, temperature, wind, all diseases that wets can both be brought into play its unique effects.Poria sweet in the mouth, light, property are flat, be used as medicine have promoting diuresis to eliminate damp pathogen, the function of strengthening the spleen stomach function regulating, mind tranquilizing and the heart calming.Modern medicine study: Poria energy enhancing human body immunity function, pachyman has obvious antitumor and protects the liver dirty effect.
Radix Arnebiae (Radix Lithospermi) is distributed in Xinjiang, Gansu and western Tibet.The ground such as the Northeast and Hebei, Henan, Shanxi, Shaanxi, Ningxia, Qinghai, Shandong, Jiangsu, Anhui, Jiangxi, Hubei, Hunan, Guangxi, Sichuan, Guizhou." Bencao Jingshu ": " Radix Arnebiae (Radix Lithospermi) is the key medicine of removing heat from blood, therefore the gas of main trusted subordinate's pathogenic heat.The five types of jaundice person damp and hotly becomes at taste, dries except the diarrhea of heat type key its subcutaneous ulcer spontaneous recovery.Pathogenic heat are interior, gas in the energy loss, and pathogenic heat are loose can invigorating the spleen and replenishing QI.Bitter cold is sliding, therefore sharp nine orifices and waterway are also.Abdomen swelling is pain person completely, damp and hot solution and from urinating, then before disease from except also.Close plaster and treat children's's variola and face acne, all the effect of removing heat from blood also.
[0015]Caulis Spatholobi: be the rattan of pulse family Climbing Plant spatholobus suberectus, Millettia dielsiana, evergreen mucuna etc.Someone thinks that this medicine comes from supplementary Amplifications of the Compendium of Materia Medica, but examines its plant description and accompanying drawing from different now.Its name that really name conforms to reality comes from the Wang Ang of Qing Dynasty essentials of Matea Medica, and other this agrostology also is loaded with the another names such as " Radix seu Caulis Verntilaginis Leiocarpae ", " Caulis seu Radix Schisandrae Henryi ".Some area such as northeast, northwest, Central-South the rattan of Lardizabalaceae liana Caulis Sargentodoxae (being Caulis Sargentodoxae, Caulis Sargentodoxae, aftermentioned) is used as Caulis Spatholobi, Yunnan is used as Caulis Spatholobi to the rattan of Magnoliacea plant Kadsura heteroclita and middle Fructus Schisandrae Chinensis.The Caulis Spatholobi main product Guangxi, the Guangdong that are just leading to, property bitter but sweet flavor temperature, return Liver Channel, there is promoting the circulation of blood to enrich blood, regulating menstruation, the effects such as relaxing muscles and tendons and activating QI and blood in the collateral can treat that the gynaecopathia such as menoxenia, blockage of menstruation, dysmenorrhea, blood deficiency amenorrhea and rheumatic arthralgia, numb hand and foot, limbs are weak and limp, blood deficiency dull yellowish colored skin etc., and controlling leukopenia also has certain curative effect.
Fructus Crataegi can enter the taste removing food stagnancy and stagnate, loose stagnated blood.Radix Bupleuri cold nature, bitter in the mouth, suffering are returned Liver Channel, gallbladder meridian, have expelling pathogenic factors from the exterior and expel the heat-evil, dispersing the stagnated live-QI to relieve the stagnation of QI, the effect of elevate a turnable ladder yang-energy.Radix Bupleuri cold nature, bitter in the mouth, suffering are returned Liver Channel, gallbladder meridian, have expelling pathogenic factors from the exterior and expel the heat-evil, dispersing the stagnated live-QI to relieve the stagnation of QI, the effect of elevate a turnable ladder yang-energy." Bencao Jingshu ": " Radix Bupleuri is the shaoyang channel medicine administered to bring out the cold.Stagnation of QI in main trusted subordinate's the intestines and stomach, diet gathers, and the cold and heat pathogen pushes away Chen Zhixin, and except dysphoria with smothery sensation person under the typhoid fever heart, foot-shaoyang gallbladder is also.Gallbladder is peace and quiet mansion, without going out without entering, khan not, emetic should not be given, purgative being prohibited, it is through at half exterior and half interior, therefore method from conciliating, the genus of Herba Sidae Rhombifoliae soup is also.Its property liter and faling apart occupies sun, therefore can reach the loose heresy of table also.Pathogens agglomerating is dysphoria with smothery sensation under the heart then, and evil loose then dysphoria with smothery sensation is explained by oneself.
Herba Taxilli bitter in the mouth, sweet, property is flat.Return liver, kidney channel.The property get a breathing space and, can rise and can fall.Clinically mainly contain two and use greatly: 1. invigorating the liver and kidney, bone and muscle strengthening, wind-damp dispelling.Articular instability, the muscles and bones flaccidity of supporting for deficiency of the liver and kindey, blood deficiency mistake is soft, soreness of waist and knee joint, such as Radix Angelicae Pubescentis et Herba Taxilli Decoction.2. nourishing blood and preventing abortion.This product energy nourishing blood and preventing abortion gas, the solid feotus vitality of the kidney invigorating is used for the blood deficiency frequent fetal movement.These product are sweet flat, and function liver and kidney tonifying, strengthening the tendons and bones, sweet in the mouth again can wind-damp dispelling, treat arthralgia pain, by lumbago due to renal deficiency, frequent fetal movement and rheumatism with the passing of time vital QI being weakened and pathogen being violent commonly used.Modern pharmacology studies show that, on the dirty specimen of the guinea-pig heart of normally beating and tremble, Herba Taxilli (electuary) all has the diastole coronary vasodilator, increase the effect of coronary flow, and can resist pituitrin. experimental results show that: total flavones 20～25mg namely has lasting coronary dilating and cardiotonic, its concentration of 1% can increase by 2～3 times of the dirty coronary flows of guinea-pig heart, and as if do not increase myocardial oxygen consumption. myocardial contraction is then suppressed first to strengthen afterwards. normal isolated rabbit ear blood vessel without direct dilating effect, but there is obviously directly dilating effect to the angiosclerotic stripped rabbit ear blood vessel of cholesterol.
Folium Nelumbinis is the leaf of nymphaeaceae plant lotus.The perennial aquatic and herbaceous of lotus is born in marshy land, pond, lakes and marhshes or the paddy field, wild or cultivation.Folium Nelumbinis contains the multiple alkaloids such as nuciferine (Roemerine), miltanthin (Pronuciferine) and nuciferine (Nuciferine) and vitamin C, polysaccharide.The effect of heat-clearing and toxic substances removing, removing heat from blood, hemostasis is arranged.The effects such as clearing away summer-heat and eliminating dampness, sending up the lucid YANG, cooling blood for hemostasis are arranged.Modern study shows, Folium Nelumbinis also has effect for reducing blood fat, so all contain Folium Nelumbinis in a lot of fat-reducing, blood fat reducing, product for resolving poxes.
Rhizoma Polygoni Cuspidati: medicinal its root, slightly warm in nature, the tool promoting blood circulation to restore menstrual flow, dampness removing function, tradition are used for the treatment of rheumatism, arthralgia pain, jaundice, amenorrhea, dysmenorrhea etc.Prove according to modern pharmacological research, Rhizoma Polygoni Cuspidati contains anthraquinone analog compound and flavonoid Multiple components, can extract polydatin with component for reducing blood fat etc. in the acting in accordance with YIN YANG changes in four seasons stem.About experiment showed, that Rhizoma Polygoni Cuspidati has the effect of cholesterol reducing and triglyceride.
(formal name used at school: Paeonia sterniana Fletcher in Journ.) also claim Paeonia sterniana Fletcher in Journ., be Ranunculaceae Paeonia plant to the Radix Paeoniae Alba.At the existing long cultivation history of China, have won fame both at home and abroad, its root also is used as medicine.The Radix Paeoniae Alba is cool in nature, and bitter in the mouth acid is slightly cold, and has the easing the affected liver of enriching blood, suppressing the hyperactive liver pain relieving.Yin fluid astringing is received the effects such as antiperspirant, is applicable to fever due to yin deficiency, menoxenia, the breast abdomen pain over the hypochondriac region, extremity contraction anxious, dysentery stomachache, spontaneous sweating, metrorrhagia, is with inferior disease.That paeoniflorin has is antibiotic, analgesic, antiinflammatory, increase coronary flow, improve the effect of myocardial nutritional flow, blood vessel dilating, antagonism acute myocardial ischemia, anticoagulant, calmness, analgesia, spasmolytic, antiulcer, adjusting blood glucose.Radix Paeoniae Alba decoct can suppress dysentery bacterium, streptococcus pneumoniae, escherichia coli, Bacillus typhi, Hemolytic streptococcus, bacillus pyocyaneus etc.
Radix Achyranthis Bidentatae (also claiming Radix Achyranthis Bidentatae), Amaranthaceae is herbaceos perennial.Claim again Herba Ophiorrhizae pumilae, to joint dish, a long-pending name cattle stem.Root is the garden cylindricality, and stem has corner angle, and joint section expands, and shape is like the knee of cattle, therefore claim Radix Achyranthis Bidentatae.The Radix Achyranthis Bidentatae drug effect is high, and Li Shizhen (1518-1593 A.D.) is said it: ' the merit of nourishing, such as the power of cattle.' Radix Achyranthis Bidentatae abnormal smells from the patient picric acid is flat, cures mainly cold-damp flaccidity syndrome and arthralgia syndrome, spasm of the limbs, the gonalgia unable to flex and stretch the extremities, by vim and vigour, the fire of getting mildewed in warm conditions is mashed, and clothes are made light of one's life by commiting suicide anti-old for a long time.The Radix Achyranthis Bidentatae of universal love is longer than liver and kidney tonifying, strong waist knee joint and invigorate blood circulation, the effect of conducting blood to flow downwards.The Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription.
The applicant is according to the therapeutic effect of above-mentioned Chinese medicine composition to hyperglycemia and/or hyperlipemic patients, component in the above-mentioned Chinese medicine composition has been carried out further preferred, the applicant finds that therapeutic effect is preferably when ingredients weight parts is following in the described Chinese medicine composition: 15 parts of Fructus Arctiis, 15 parts of Rhizoma dioscoreaes, 8 parts of Semen Cassiaes, 12 parts of Rhizoma Alismatis, 15 parts in Rhizoma Curcumae Longae, 14 parts in Poria, 8 parts of Radix Arnebiae (Radix Lithospermi)s, 25 parts of Caulis Spatholobis, 25 parts of Fructus Crataegis, 12 parts of Radix Bupleuri, 14 parts of Herba Taxillis, 20 parts on Folium Nelumbinis, 15 parts of Rhizoma Polygoni Cuspidati, 9 parts of the Radix Paeoniae Albas, 12 parts in 18 parts of Radix Achyranthis Bidentataes and Radix Glycyrrhizae.
As an embodiment preferred for this invention, can also further comprise 15 parts of 8 parts of Radix Et Rhizoma Rhei and Fructus Ligustri Lucidi in the above-mentioned Chinese medicine composition.Two kinds of medicines and above-mentioned Chinese medicine composition coupling can further strengthen Chinese medicine composition to the therapeutic effect of hyperlipidemia and/or hyperglycemia, and can reduce medicine to the drug toxicity of body.Its dry rhizome of Elsholtzia, the nature and flavor bitter cold is returned spleen, stomach, large intestine, liver, the pericardium Five Classics.Tool purging heat to relax the bowels, removing mass clots absorbing, clearing away damp-heat function.Pharmacological research confirms, Radix Et Rhizoma Rhei energy blood pressure lowering, cholesterol reducing.Modern pharmacy studies confirm that, it is main to contain the anthracene ester derivant, comprises emodin, chrysophanol, chrysophanic acid, aloe-emodin, and the glycoside of tanning.Has the effect that reduces blood pressure with cholesterol reducing.Wherein emodin, chrysophanic acid, aloe-emodin promote the secretion of bile, and the cholesterol reducing effect is the strongest.The traditional Chinese medical science is thought: Radix Et Rhizoma Rhei can be captured stagnant, removing pathogenic heat from blood and toxic substance from the body, and eliminating blood stasis and inducing menstruation, promoting the function of the gallbladder to alleviate jaundice is to capture to purge heat, the key medicine of blood stasis removing detumescence.The Fructus Ligustri Lucidi flavor: sweet in the mouth, hardship, cool in nature, return liver, kidney channel.Have the tonifying liver kidney yin, crow must make eye bright, and modern medicine study thinks that the effect that Fructus Ligustri Lucidi can suppress helicobacter pylori can treat gastropathy, also has and suppresses the treatment that the purine abnormal metabolism is used for gout and hyperuricemia.Cure mainly: be used for the hepatic and renal YIN deficiency, soreness of waist tinnitus, early whitening of beard and hair; Unseeing, poor vision; Fever due to yin deficiency, gastropathy and gout and and hyperuricemia.The pharmaceutical research demonstration, Fructus Ligustri Lucidi coarse powder 20g/ only admixes feed in the foodstuff, can reduce serum ornitrol and content of triglyceride to Experimental Hyperlipemia disease rabbit, and aorta Lipid Plaque and the formation of crown atherosclerotic plaque are subdued.Fructus Ligustri Lucidi composition oleanolic acid 30mg/kg admixes beverage feed rat, and 0.4% olive ester suspension 0.5ml all has effect for reducing blood fat to the rabbit gavage to hyperlipidemia rat, rabbit.Oleanolic acid 30,60mg/kg are added on 8 weeks of feed Japanese quail in the feedstuff, obviously reduce the total cholesterol of serum, lipid peroxide, the total cholesterol content of arterial wall, reduce atherosclerotic incidence rate.Oleanolic acid 50,100mg/kg subcutaneous injection, continuous 7 days, can reduce normal mouse blood glucose, the diabetes mice that alloxan is caused has prevention and therapeutical effect, also can the mouse blood sugar that antiadrenergic drug or glucose cause be raise.
The method for preparing Chinese medicine composition of the present invention is as follows: get each medical material of above-mentioned components by weight percent, add the 5-15 water doubly of medical material gross weight, soaked 10-60 minute, decoct 1-4 time, each 1-3 hour, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.05-1.25, and this relative density is the testing result under 60 degrees centigrade, adds ethanol and is 60-90%(v/v to containing the alcohol amount), left standstill 24 hours, get supernatant, Recycled ethanol is extremely concentrated, and get final product.The above-mentioned Chinese medicine composition of the present invention can further be prepared into pharmaceutical preparation commonly used clinically, is preferably mixture, tablet, capsule.
The present invention also discloses a kind of medical usage of above-mentioned Chinese medicine composition, i.e. the purposes of above-mentioned Chinese medicine composition in preparation treatment hyperglycemia and/or high blood cholesterol drug.The present invention has obtained excellent therapeutic effect to above-mentioned disease, and especially the patient treatment effect to hyperlipidemia merging hyperglycemia is more remarkable.The embodiment of the invention 7 confirms, no matter fasting glucose or post-prandial glycemia, Chinese medicine composition group of the present invention has been compared utmost point significant difference or significant difference with positive controls with model group, this shows that each group treatment Hyperglycemia In Stz-induced Diabetic Rats disease of Chinese medicine composition of the present invention all has good blood sugar reducing function.In addition, Chinese medicine composition group of the present invention is being better than positive controls aspect the blood glucose reduction, and wherein part relatively has significant difference with positive controls.The level of T-CHOL, triglyceride, HDL-C and the low-density lipoprotein cholesterol of each group of Chinese medicine composition of the present invention has been compared significant difference or utmost point significant difference with model group simultaneously, and this shows that each group of Chinese medicine composition of the present invention is all having good effect for reducing fat aspect the treatment hyperlipidemia.In addition, Chinese medicine composition group of the present invention is being better than positive controls aspect the blood fat reduction, and wherein part relatively has significant difference with positive controls.This shows that Chinese medicine composition of the present invention has good therapeutic effect for hyperlipidemia and/or hyperglycemic patients.
In a word, the present invention compared with prior art has the activity of fine treatment hyperglycemia and/or hyperlipidemia, and can the present invention be pure Chinese medicinal preparation, to human body particularly to the liver avirulence.When the present invention used as hyperglycemia and/or hyperlipidemia medicine, drug effect was comprehensive, conditions of patients is taken a turn for the better, and can fundamentally alleviate the pathogenic factor of disease; And Chinese medicine composition preparation of the present invention is simple, and substantially nontoxic, raw material is easy to get, and is suitable for popular use, has good application prospect.
The specific embodiment
Below further describe the present invention by specific embodiment, but the present invention is not limited only to following examples.Within the scope of the invention or within not breaking away from content of the present invention, spirit and scope, Chinese medicine composition of the present invention is suitably improved, replaces the identical component of effect, will become apparent to those skilled in the art that they all are deemed to be included within the scope of the present invention.
The preparation of first's Chinese medicine composition of the present invention
Embodiment 1 Chinese medicine composition mixture of the present invention
Prescription: 10 parts of Fructus Arctiis, 12 parts of Rhizoma dioscoreaes, 6 parts of Semen Cassiaes, 10 parts of Rhizoma Alismatis, 10 parts in Rhizoma Curcumae Longae, 12 parts in Poria, 6 parts of Radix Arnebiae (Radix Lithospermi)s, 20 parts of Caulis Spatholobis, 20 parts of Fructus Crataegis, 10 parts of Radix Bupleuri, 12 parts of Herba Taxillis, 15 parts on Folium Nelumbinis, 10 parts of Rhizoma Polygoni Cuspidati, 6 parts of the Radix Paeoniae Albas, 10 parts in 15 parts of Radix Achyranthis Bidentataes and Radix Glycyrrhizae.
Preparation method: get each medical material of above-mentioned components by weight percent, add 5 times water of medical material gross weight, soaked 30 minutes, decoct 2 times, each 2 hours, filter, merging filtrate, filtrate decompression are concentrated into the extractum of relative density 1.1, and this relative density is the testing result under 60 degrees centigrade, add ethanol and be 75%(v/v to containing the alcohol amount), left standstill 24 hours, get supernatant, Recycled ethanol is concentrated, adds water to 1000ml, stirs evenly, packing, flowing steam sterilization 35min namely gets mixture.
Embodiment 2 Chinese medicine composition tablets of the present invention
Prescription: 20 parts of Fructus Arctiis, 18 parts of Rhizoma dioscoreaes, 10 parts of Semen Cassiaes, 15 parts of Rhizoma Alismatis, 20 parts in Rhizoma Curcumae Longae, 16 parts in Poria, 9 parts of Radix Arnebiae (Radix Lithospermi)s, 30 parts of Caulis Spatholobis, 30 parts of Fructus Crataegis, 16 parts of Radix Bupleuri, 18 parts of Herba Taxillis, 25 parts on Folium Nelumbinis, 20 parts of Rhizoma Polygoni Cuspidati, 12 parts of the Radix Paeoniae Albas, 15 parts in 20 parts of Radix Achyranthis Bidentataes and Radix Glycyrrhizae.
Preparation method: get each medical material of above-mentioned components by weight percent, add 10 times water of medical material gross weight, soaked 60 minutes, decoct 1 time, each 1 hour, filter, merging filtrate, filtrate decompression are concentrated into the extractum of relative density 1.25, and this relative density is the testing result under 60 degrees centigrade, add ethanol and be 80%(v/v to containing the alcohol amount), left standstill 24 hours, and got supernatant, Recycled ethanol is to concentrated, vacuum drying, granulation, tabletting and get final product.
Embodiment 3 Chinese medicinal composition capsules of the present invention
Prescription: 15 parts of Fructus Arctiis, 15 parts of Rhizoma dioscoreaes, 8 parts of Semen Cassiaes, 12 parts of Rhizoma Alismatis, 15 parts in Rhizoma Curcumae Longae, 14 parts in Poria, 8 parts of Radix Arnebiae (Radix Lithospermi)s, 25 parts of Caulis Spatholobis, 25 parts of Fructus Crataegis, 12 parts of Radix Bupleuri, 14 parts of Herba Taxillis, 20 parts on Folium Nelumbinis, 15 parts of Rhizoma Polygoni Cuspidati, 9 parts of the Radix Paeoniae Albas, 12 parts in 18 parts of Radix Achyranthis Bidentataes and Radix Glycyrrhizae.
Preparation method: get each medical material of above-mentioned components by weight percent, add 8 times water of medical material gross weight, soaked 45 minutes, decoct 4 times, each 1.5 hours, filter, merging filtrate, filtrate decompression are concentrated into the extractum of relative density 1.2, and this relative density is the testing result under 60 degrees centigrade, add ethanol and be 90%(v/v to containing the alcohol amount), left standstill 24 hours, get supernatant, Recycled ethanol is to concentrated, vacuum drying is granulated, and is encapsulated and get final product.
Embodiment 4 Chinese medicine composition mixture of the present invention
Prescription: 10 parts of Fructus Arctiis, 12 parts of Rhizoma dioscoreaes, 6 parts of Semen Cassiaes, 10 parts of Rhizoma Alismatis, 10 parts in Rhizoma Curcumae Longae, 12 parts in Poria, 6 parts of Radix Arnebiae (Radix Lithospermi)s, 20 parts of Caulis Spatholobis, 20 parts of Fructus Crataegis, 10 parts of Radix Bupleuri, 12 parts of Herba Taxillis, 15 parts on Folium Nelumbinis, 10 parts of Rhizoma Polygoni Cuspidati, 6 parts of the Radix Paeoniae Albas, 15 parts of Radix Achyranthis Bidentataes, 10 parts in Radix Glycyrrhizae, 15 parts of 8 parts of Radix Et Rhizoma Rhei and Fructus Ligustri Lucidi.
Preparation method: get each medical material of above-mentioned components by weight percent, add 5 times water of medical material gross weight, soaked 30 minutes, decoct 2 times, each 2 hours, filter, merging filtrate, filtrate decompression are concentrated into the extractum of relative density 1.1, and this relative density is the testing result under 60 degrees centigrade, add ethanol and be 75%(v/v to containing the alcohol amount), left standstill 24 hours, get supernatant, Recycled ethanol is concentrated, adds water to 1000ml, stirs evenly, packing, flowing steam sterilization 35min namely gets mixture.
Embodiment 5 Chinese medicine composition tablets of the present invention
Prescription: 20 parts of Fructus Arctiis, 18 parts of Rhizoma dioscoreaes, 10 parts of Semen Cassiaes, 15 parts of Rhizoma Alismatis, 20 parts in Rhizoma Curcumae Longae, 16 parts in Poria, 9 parts of Radix Arnebiae (Radix Lithospermi)s, 30 parts of Caulis Spatholobis, 30 parts of Fructus Crataegis, 16 parts of Radix Bupleuri, 18 parts of Herba Taxillis, 25 parts on Folium Nelumbinis, 20 parts of Rhizoma Polygoni Cuspidati, 12 parts of the Radix Paeoniae Albas, 20 parts of Radix Achyranthis Bidentataes, 15 parts in Radix Glycyrrhizae, 15 parts of 8 parts of Radix Et Rhizoma Rhei and Fructus Ligustri Lucidi.
Preparation method: get each medical material of above-mentioned components by weight percent, add 10 times water of medical material gross weight, soaked 60 minutes, decoct 1 time, each 1 hour, filter, merging filtrate, filtrate decompression are concentrated into the extractum of relative density 1.25, and this relative density is the testing result under 60 degrees centigrade, add ethanol and be 80%(v/v to containing the alcohol amount), left standstill 24 hours, and got supernatant, Recycled ethanol is to concentrated, vacuum drying, granulation, tabletting and get final product.
Embodiment 6 Chinese medicinal composition capsules of the present invention
Prescription: 15 parts of Fructus Arctiis, 15 parts of Rhizoma dioscoreaes, 8 parts of Semen Cassiaes, 12 parts of Rhizoma Alismatis, 15 parts in Rhizoma Curcumae Longae, 14 parts in Poria, 8 parts of Radix Arnebiae (Radix Lithospermi)s, 25 parts of Caulis Spatholobis, 25 parts of Fructus Crataegis, 12 parts of Radix Bupleuri, 14 parts of Herba Taxillis, 20 parts on Folium Nelumbinis, 15 parts of Rhizoma Polygoni Cuspidati, 9 parts of the Radix Paeoniae Albas, 18 parts of Radix Achyranthis Bidentataes, 12 parts in Radix Glycyrrhizae, 15 parts of 8 parts of Radix Et Rhizoma Rhei and Fructus Ligustri Lucidi.
Preparation method: get each medical material of above-mentioned components by weight percent, add 8 times water of medical material gross weight, soaked 45 minutes, decoct 4 times, each 1.5 hours, filter, merging filtrate, filtrate decompression are concentrated into the extractum of relative density 1.2, and this relative density is the testing result under 60 degrees centigrade, add ethanol and be 90%(v/v to containing the alcohol amount), left standstill 24 hours, get supernatant, Recycled ethanol is to concentrated, vacuum drying is granulated, and is encapsulated and get final product.
Second portion Chinese medicine composition drug effect of the present invention is partly investigated
Embodiment 7 pharmaceutical compositions of the present invention merge the impact of hyperlipemia rat model on hyperglycemia
1, the preparation of model
Male Wistar rat, body weight 180～220g, animal is at first screened, and the animal performance is escaped rapidly, is screamed, erects tail, pants and be difficult for being adapted to standard when stimulating to give first foot shock and noise, elects as originally and zoologizes.Animal is raised in cages separately in stimulating cage.At first normally raise a week before beginning to stimulate, then beginning stimulates, and stimulates stimulus intensity every day 2 times: each 2 h of upper and lower noon, continued stimulus is 8 weeks approximately, give simultaneously the high sugar of high fat and high protein feed.After finishing, modeling does the carbohydrate tolerance test test.Oral glucose tolerance test (OGTT): behind the rat fasting 12h, with 2.5g/kg dosage gavage 50% glucose solution, the tail venous blood sampling detects the blood glucose value of 2h, and superseded blood glucose is lower than the rat of 6.20mmol/L, superseded body weight is lower than the rat of 350g, then grouping and administration.
2, grouping and administration
Administration: after the modeling success, give respectively following drug administration, each organizes gastric infusion, and once a day, the administration volume is 10ml/kg.Totally 8 weeks.
Model control group: gavage gives with the volume normal saline;
Positive controls: gavage gives SHENQI JIANGTANG sheet (Guangdong Wannianqing Pharmaceutical Co., Ltd.'s production), crude drug amount 5mg/kg;
1 group in Chinese medicine: gavage gives the embodiment of the invention 1 described Chinese medicine composition, crude drug amount 5mg/kg;
2 groups in Chinese medicine: gavage gives the embodiment of the invention 2 described Chinese medicine compositions, crude drug amount 5mg/kg;
3 groups in Chinese medicine: gavage gives the embodiment of the invention 3 described Chinese medicine compositions, crude drug amount 5mg/kg;
4 groups in Chinese medicine: gavage gives the embodiment of the invention 4 described Chinese medicine compositions, crude drug amount 5mg/kg;
5 groups in Chinese medicine: gavage gives the embodiment of the invention 5 described Chinese medicine compositions, crude drug amount 5mg/kg;
6 groups in Chinese medicine: gavage gives the embodiment of the invention 6 described Chinese medicine compositions, crude drug amount 5mg/kg;
7 groups in Chinese medicine: gavage gives the embodiment of the invention 1 described Chinese medicine composition, crude drug amount 1mg/kg;
8 groups in Chinese medicine: gavage gives the embodiment of the invention 1 described Chinese medicine composition, crude drug amount 20mg/kg;
Every group 8, still to feed with high lipid food during the administration, every day, gavage was three times, respectively in 6:00,14:00,22:00 gavage, continuous 8 weeks.
3, detect index
3.1 each group of carbohydrate tolerance test table 1 Chinese medicine composition is on the impact of rat carbohydrate tolerance
*Compare P＜0.05 with model group;
*Compare P＜0.01 with model group;
▼Compare P＜0.05 with positive controls.
After administration finished, water 8h was can't help in the rat fasting, cut tail and got blood, measured fasting glucose with micro-blood glucose meter.After having surveyed, the Glucose Liquid gavage with 25% (determining the amount of glucose by body weight, i.e. 2.5g/kg) is again cut tail and is got blood behind the 2h, measures post-prandial glycemia with micro-blood glucose meter.Calculate the difference of post-prandial glycemia and fasting glucose.The result shows, no matter fasting glucose or post-prandial glycemia, Chinese medicine composition group of the present invention (particularly Chinese medicine 3 groups with 6 groups) has been compared utmost point significant difference or significant difference with positive controls with model group, this shows that each group treatment Hyperglycemia In Stz-induced Diabetic Rats disease of Chinese medicine composition of the present invention all has good blood sugar reducing function.In addition, Chinese medicine composition group of the present invention is being better than positive controls aspect the blood glucose reduction, and wherein part relatively has significant difference with positive controls.
3.2 each group of mensuration table 2 Chinese medicine composition of blood fat is on the impact of rat fat
*Compare P＜0.05 with model group;
*Compare P＜0.01 with model group;
▼Compare P＜0.05 with positive controls.
After administration finishes, detect serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), HDL-C (HDL-C), triglyceride (TG).The result shows, the level of T-CHOL, triglyceride, HDL-C and the low-density lipoprotein cholesterol of each group of Chinese medicine composition of the present invention has been compared significant difference or utmost point significant difference with model group, this shows that each group (particularly Chinese medicine is 3 groups and 6 groups) of Chinese medicine composition of the present invention is all having good effect for reducing fat aspect the treatment hyperlipidemia.In addition, Chinese medicine composition group of the present invention is being better than positive controls aspect the blood fat reduction, and wherein part relatively has significant difference with positive controls.
Claims (9)
1. treat the Chinese medicine composition that hyperlipidemia merges hyperglycemia for one kind, it is characterized in that being made by the raw material of following weight portion: Fructus Arctii 10-20 part, Rhizoma dioscoreae 12-18 part, Semen Cassiae 6-10 part, Rhizoma Alismatis 10-15 part, Rhizoma Curcumae Longae 10-20 part, Poria 12-16 part, Radix Arnebiae (Radix Lithospermi) 6-9 part, Caulis Spatholobi 20-30 part, Fructus Crataegi 20-30 part, Radix Bupleuri 10-16 part, Herba Taxilli 12-18 part, Folium Nelumbinis 15-25 part, Rhizoma Polygoni Cuspidati 10-20 part, Radix Paeoniae Alba 6-12 part, Radix Achyranthis Bidentatae 15-20 part and Radix Glycyrrhizae 10-15 part.
2. treat as claimed in claim 1 hyperlipidemia and merge the Chinese medicine composition of hyperglycemia, it is characterized in that: the raw material of described Chinese medicine composition also comprises 15 parts of 8 parts of Radix Et Rhizoma Rhei and Fructus Ligustri Lucidi.
3. treat as claimed in claim 1 the Chinese medicine composition of hyperlipidemia merging hyperglycemia, it is characterized in that being made by the raw material of following weight portion: 15 parts of Fructus Arctiis, 15 parts of Rhizoma dioscoreaes, 8 parts of Semen Cassiaes, 12 parts of Rhizoma Alismatis, 15 parts in Rhizoma Curcumae Longae, 14 parts in Poria, 8 parts of Radix Arnebiae (Radix Lithospermi)s, 25 parts of Caulis Spatholobis, 25 parts of Fructus Crataegis, 12 parts of Radix Bupleuri, 14 parts of Herba Taxillis, 20 parts on Folium Nelumbinis, 15 parts of Rhizoma Polygoni Cuspidati, 9 parts of the Radix Paeoniae Albas, 12 parts in 18 parts of Radix Achyranthis Bidentataes and Radix Glycyrrhizae.
4. treat as claimed in claim 3 hyperlipidemia and merge the Chinese medicine composition of hyperglycemia, it is characterized in that: the raw material of described Chinese medicine composition also comprises 15 parts of 8 parts of Radix Et Rhizoma Rhei and Fructus Ligustri Lucidi.
5. the treatment hyperlipidemia merges the Chinese medicine composition of hyperglycemia as described in arbitrary such as claim 1-4, and it is characterized in that: described Chinese medicine composition is mixture, tablet or capsule.
6. the treatment hyperlipidemia merges the preparation method of the Chinese medicine composition of hyperglycemia as described in arbitrary such as claim 1-4, it is characterized in that comprising following processing step: each medical material of getting above-mentioned components by weight percent, the 5-15 water doubly that adds the medical material gross weight, soaked 10-60 minute, decoct 1-4 time, each 1-3 hour, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.05-1.25, this relative density is the testing result under 60 degrees centigrade, add ethanol to containing the alcohol amount for 60-90%v/v, left standstill 24 hours, get supernatant, Recycled ethanol is extremely concentrated, and get final product.
7. treat as claimed in claim 1 hyperlipidemia and merge the hyperglycemia Chinese medicine composition, the purposes in preparation treatment hyperglycemia medicine.
8. treat as claimed in claim 1 hyperlipidemia and merge the hyperglycemia Chinese medicine composition, the purposes in preparation treatment high blood cholesterol drug.
9. treat as claimed in claim 1 the Chinese medicine composition of hyperlipidemia merging hyperglycemia, the purposes in preparation treatment hyperlipidemia merging hyperglycemia medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102817934A CN103301413A (en) | 2013-07-08 | 2013-07-08 | Traditional Chinese medicine composition for treating hyperlipemia and hyperglycemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102817934A CN103301413A (en) | 2013-07-08 | 2013-07-08 | Traditional Chinese medicine composition for treating hyperlipemia and hyperglycemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103301413A true CN103301413A (en) | 2013-09-18 |
Family
ID=49127419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013102817934A Pending CN103301413A (en) | 2013-07-08 | 2013-07-08 | Traditional Chinese medicine composition for treating hyperlipemia and hyperglycemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103301413A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103621959A (en) * | 2013-11-11 | 2014-03-12 | 界首市宏亮食品有限公司 | Spice with soup for lipid-lowering spiced beef |
| CN103719495A (en) * | 2013-12-31 | 2014-04-16 | 青岛恒波仪器有限公司 | Great burdock achene healthcare tea for reducing blood glucose and lipid and preparation method thereof |
| CN105168323A (en) * | 2015-09-03 | 2015-12-23 | 佛山市朗达信息科技有限公司 | Composition with blood-fat-reducing effect and preparation method of composition |
| CN106109636A (en) * | 2016-08-18 | 2016-11-16 | 张志航 | A kind of Chinese medicine composition treating hyperlipidemia |
| CN106511904A (en) * | 2016-12-17 | 2017-03-22 | 郑州郑先医药科技有限公司 | Traditional Chinese medicine and western medicine composition for treating hyperlipidemia and preparation method of traditional Chinese medicine and western medicine composition |
| CN112755155A (en) * | 2021-02-07 | 2021-05-07 | 元莱健康产品(武汉)有限公司 | Composition for protecting liver and kidney, regulating immunity and improving physique and preparation method thereof |
| CN116920061A (en) * | 2022-03-30 | 2023-10-24 | 北京精医和生医药科技有限公司 | Traditional Chinese medicine composition for treating hyperglycemia and preparation method thereof |
-
2013
- 2013-07-08 CN CN2013102817934A patent/CN103301413A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 仝小林等: "《第九次全国中医糖尿病学术大会论文汇编》", 1 September 2006 * |
| 黎海彬: "降脂中药的研究进展", 《广州城市职业学院学报》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103621959A (en) * | 2013-11-11 | 2014-03-12 | 界首市宏亮食品有限公司 | Spice with soup for lipid-lowering spiced beef |
| CN103719495A (en) * | 2013-12-31 | 2014-04-16 | 青岛恒波仪器有限公司 | Great burdock achene healthcare tea for reducing blood glucose and lipid and preparation method thereof |
| CN105168323A (en) * | 2015-09-03 | 2015-12-23 | 佛山市朗达信息科技有限公司 | Composition with blood-fat-reducing effect and preparation method of composition |
| CN106109636A (en) * | 2016-08-18 | 2016-11-16 | 张志航 | A kind of Chinese medicine composition treating hyperlipidemia |
| CN106511904A (en) * | 2016-12-17 | 2017-03-22 | 郑州郑先医药科技有限公司 | Traditional Chinese medicine and western medicine composition for treating hyperlipidemia and preparation method of traditional Chinese medicine and western medicine composition |
| CN112755155A (en) * | 2021-02-07 | 2021-05-07 | 元莱健康产品(武汉)有限公司 | Composition for protecting liver and kidney, regulating immunity and improving physique and preparation method thereof |
| CN116920061A (en) * | 2022-03-30 | 2023-10-24 | 北京精医和生医药科技有限公司 | Traditional Chinese medicine composition for treating hyperglycemia and preparation method thereof |
| CN116920061B (en) * | 2022-03-30 | 2024-05-17 | 北京精医和生医药科技有限公司 | Traditional Chinese medicine composition for treating hyperglycemia and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103719498B (en) | A kind of Siberian solomonseal rhizome health-care tea improving immunity and preparation method thereof | |
| CN104435775A (en) | Chinese medicinal health-care spirit and preparation method thereof | |
| CN103990081B (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating infant jaundice | |
| CN103301413A (en) | Traditional Chinese medicine composition for treating hyperlipemia and hyperglycemia | |
| CN102784363A (en) | Traditional Chinese medicine composition for treating pancreatic cancer and preparation method thereof | |
| CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
| CN101607051B (en) | Traditional Chinese medicine composition for losing weight and preparation method thereof | |
| CN104338043A (en) | Drug for improving immunity and preparation method thereof | |
| CN103301267B (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
| CN105124078A (en) | Gardenia blood-glucose-reducing and lipid-reducing healthcare tea and preparing method thereof | |
| CN105194421A (en) | Self-heal health-care oral solution capable of reducing blood fat and preparation method thereof | |
| CN106177477A (en) | A kind of health composition for blood sugar lowering, blood fat reducing and blood pressure lowering | |
| CN104815037A (en) | Drug for treating rheumatism accumulated toxin type chronic eczema and preparation method of drug | |
| CN104206595A (en) | Blood lipid and blood glucose reducing Chinese wolfberry root-bark health care tea and preparation method thereof | |
| CN103877438A (en) | Traditional Chinese medicine preparation for treating gout and production method thereof | |
| CN103550505A (en) | Traditional Chinese medicine preparation for treating qi-yin deficiency type diabetes | |
| CN104286864B (en) | A kind of semen astragali complanati oral liquid improving immunity and preparation method thereof | |
| CN103705860B (en) | A kind of Chinese medicine composition for the treatment of infant jaundice and preparation method thereof | |
| CN103007111A (en) | Chinese medicinal preparation for treating diarrhea of rabbits and preparation method of Chinese medicinal preparation | |
| CN106215118A (en) | Antineoplastic health preparation and preparation method thereof | |
| CN106334171A (en) | Traditional Chinese medicine preparation for repairing liver damage and preparation method thereof | |
| CN105343593A (en) | Spica prunellae health oral liquid capable of decreasing blood pressure and blood lipid as well as preparation method of spica prunellae health oral liquid | |
| CN101869603A (en) | Traditional Chinese medicine composition for protecting liver and preventing liver damage and preparation method thereof | |
| CN107125751B (en) | Tortoise powder, preparation method and application thereof | |
| CN105062810A (en) | Saussurea involucrate prepared wine and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130918 |